Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SMA-TB

Financiado

Cerrado

A novel Stratified Medicine Algorithm to predict treatment responses to host dir...

A novel Stratified Medicine Algorithm to predict treatment responses to host directed therapy in TB patients. Tuberculosis (TB) is a chronic, life-threatening infectious disease which poses a tremendous challenge for physicians, researchers and Health Systems, which treatment is long, based only on the drug susceptibility of the responsib... ver más

31/12/2024

FUNDACIO INSTITUT...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

FUNDACIO INSTITUT D'INVESTIGACIO EN CIENCIES... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 12M€

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-12-31

SC1-BHC-14-2019: Stratified host-directed approaches... Specific Challenge:Despite major advances in development of new drugs and vaccines against infectiou...

I+D

Cerrada hace 6 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

FUNDACIO INSTITUT D'INVESTIG...

1.68M€ | Lider

WITS HEALTH CONSORTIUM (PTY)...

LIO

124.91K€ | Participante

Innovasjon Norge

840.13K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 60 meses Fecha Inicio: 2019-12-06
Fecha Fin: 2024-12-31

Líder del proyecto

FUNDACIO INSTITUT D'INVESTIGACIO EN CIENCIES... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 12M€

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Tuberculosis (TB) is a chronic, life-threatening infectious disease which poses a tremendous challenge for physicians, researchers and Health Systems, which treatment is long, based only on the drug susceptibility of the responsible infective strain and very costly in drug-resistant cases (MDR-TB). The European Region still has the highest prevalence of MDR-TB in the world. Host-Directed Therapies (HDT) have been recently proposed to shorten treatment length and by to improve the patients’ outcomes while not increasing the risk of generating drug resistance. As hyperinflammation is responsible of the lung damage associated to patients’ worse outcomes and sequelae, one of the approaches is to add an HDT with anti-inflammatory effect to the current drug regimen to cure the patients faster while having less permanent lung damage. Because TB has a wide range of clinical forms and severity stages, any therapeutic regimen needs to be studied in clinical trials (CT) as its benefit might differ among patients. No individualized personalized medicine is possible without stratifying the patients by integrating pathogen and host factors that will predict the course of the disease and the response to the intervention. SMA-TB objectives are: • To evaluate in a CT the potential impact of acetylsalicylic acid (ASA) and Ibuprofen (Ibu) (anti-inflammatoriesy HDT) as adjuncts to standard therapy for drug sensitive (DS-) and MDR-TB. This potentially will reduce tissue damage, decrease the length of the treatment and the risk of bad outcomes. • To identify and clinically validate host and pathogen biomarkers for further selection according to their relevance in terms of their ability to predict TB course and outcomes and response to treatment thanks to data science protocol. • To generate a medical algorithm to stratify patients using network-based mathematical modelling for predicting the course of the disease and its response to the intervention, to be applied during clinical management to improve and personalize TB.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores